Blood Test Might Replace Bone Marrow Biopsy

Quest Diagnostics has been granted an exclusive license from The M. D. Anderson Cancer Center to use five proprietary blood testing methods, which, once available in the form of laboratory diagnostic tests, may eliminate the need for painful and expensive bone marrow and other tissue extractions. The tests are intended to provide a safer, less painful tool for the diagnosis, treatment and monitoring of leukemia and lymphoma in cancer patients. The initial tests are expected as early as the end of this year.



Current diagnostic and monitoring tests for leukemia and lymphoma patients often require patients to undergo painful procedures, such as bone marrow biopsies which require extraction of tissue with a large needle. The new tests have the potential to provide a more clinically useful assessment of prognosis, disease progression, and therapeutic success, which could enable oncologists to advance the efficacy of therapies.



"Our research has shown that testing for tumor onstituents in the blood provides a more clinically useful assessment of a patient's disease status because it shows what is happening in the entire body, compared with biopsies where a tissue sample only provides information about a specific area," said Michael J. Keating, M.D., Professor of Medicine and Deputy Department Chairman for the Department of Leukemia at M. D. Anderson Cancer Center.



News Release

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap